A handheld breath test that flags lung-cancer risk from a ten-second sample. Low-dose CT catches these cancers early but rarely reaches the people who need it, so we designed Pulma to cost about $100.
One cheap gas sensor can’t tell hexanal from pentane, so Pulma reads the overall pattern of volatile organic compounds instead, the way a nose recognises smells, and a model turns that pattern into a risk score. SHAP analysis showed it relying on aldehydes and alkanes, which are linked to tumour-related oxidative stress. It’s a risk-stratification tool, not a diagnosis.
- Breathe10 seconds into the mouthpiece
- SenseA BME688 sensor reads the VOCs
- ScoreSent to the app over Bluetooth
- ReferRisk level, and whether to see a doctor
- Price
- About $100, plus $5 a month
- Reviewed at
- Banphaeo, Rajavithi and Ramathibodi hospitals
- Patent
- Thai petty patent 2603006842
- Team
- With Burich Benjarattananon
Recognition
- Gold MedaliCAN 2026, International Invention Innovation Competition, Toronto
- Special AwardTISIAS, Toronto International Society of Innovation & Advanced Skills
- Great Special AwardHIUF, Highly Innovative Unique Foundation, Saudi Arabia
Advised by Dr. Sirima Eursritanakorn, Head of Radiology at Rajavithi Hospital; Dr. Passawan Sukontket, medical oncologist at Banphaeo Hospital; and Prof. Wiwat Wajanavisit, MD, of Ramathibodi Hospital.